

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

- (1) RESIGNATION OF DIRECTORS, CHAIRPERSON OF THE BOARD,
AND CHIEF EXECUTIVE OFFICER;
(2) RE-DESIGNATION AND APPOINTMENT OF DIRECTORS;
(3) CHANGE OF AUTHORISED REPRESENTATIVE AND
COMPLIANCE OFFICER;
AND
(4) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board hereby announces the following (1) resignation of the Directors, chairperson of the Board, and chief executive officer; (2) re-designation and appointment of the Directors; (3) change of the Authorised Representative and Compliance Officer; and (4) change in composition of Board committees, all with effect from 1 August 2022:

1. Mr. CHAN Ting has resigned as the executive Director, chairperson of the Board, chief executive officer, Authorised Representative, Compliance Officer, chairperson and member of the Nomination Committee and member of the Remuneration Committee;
2. Madam CHEUNG Kwai Lan has resigned as the non-executive Director and honorary chairperson of the Company;
3. Mr. CHAU Wai Wah Fred has been re-designated from independent non-executive Director to executive Director of the Company, has been appointed as an Authorised Representative and Compliance Officer, and has ceased to act as a member of the Audit Committee; and
4. Mr. LAM Kit Sun has been appointed as an independent non-executive Director of the Company, a member of the Audit Committee and the Remuneration Committee and the chairperson and member of the Nomination Committee.

(1) RESIGNATION OF DIRECTORS, CHAIRPERSON OF THE BOARD, AND CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) hereby announces that with effect from 1 August 2022:

Mr. CHAN Ting (“**Mr. CHAN**”) has resigned as the executive Director, chairperson of the Board and chief executive officer of the Company in order to devote more time to his personal commitments. Madam CHEUNG Kwai Lan (“**Madam CHEUNG**”) has resigned as the non-executive Director and honorary chairperson of the Company as she would like to devote more time to her family. Mr. CHAN and Madam CHEUNG have confirmed that they have no disagreement with the Board and there are no other matters relating to their resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. CHAN and Madam CHEUNG for their valuable contribution to the Company during their tenure of office.

(2) RE-DESIGNATION AND APPOINTMENT OF DIRECTORS

The Board is pleased to announce that with effect from 1 August 2022:

Mr. CHAU Wai Wah Fred (“**Mr. CHAU**”) has been re-designated from independent non-executive Director to executive Director of the Company; and

Mr. Lam Kit Sun (“**Mr. LAM**”) has been appointed as an independent non-executive Director of the Company.

Mr. CHAU Wai Wah Fred

Mr. CHAU Wai Wah Fred, aged 60, is a member of the remuneration committee and nomination committee of the Company and was an independent non-executive Director and a member of the audit committee of the Company. He was formerly the Head of the Office of Dutiable Commodities Administration of Hong Kong Customs and Excise Department (C&ED) and retired with rank of Senior Superintendent. He has served the C&ED for 34 years with wide range of exposure including intellectual property rights (IPR) protection, anti-smuggling, anti-narcotics, intelligence and liaisons and dutiable commodities administration. Mr. Chau has served as the Divisional Commander and Group Head of the Intellectual Property Investigation Bureau to combat on organized transnational crimes, in particular in IPR infringement cases with the Mainland and overseas counterparts. Mr. Chau was awarded the honours of Customs and Excise Medal for Meritorious Service (C.M.S.M.) by the Chief Executive in the 2017 honours presentation ceremony.

Mr. CHAU has not entered into any service contract for his duties as the executive Director with the Company. He will be entitled to receive an annual salary of HK\$240,000 and an annual director’s fee of HK\$60,000 which were determined by the Board based on

recommendation of the remuneration committee of the Company and with reference to his relevant roles, duties and responsibilities in the Company, the prevailing market conditions and the Company's performance. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

As at the date of this announcement, Mr. CHAU is interested in 3,800,000 shares and 3,600,000 share options of the Company. Save as disclosed above, Mr. CHAU (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the "SFO"); (ii) does not hold any directorship in any Hong Kong or overseas listed public companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on GEM ("GEM") of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules")) of the Company nor does he hold any position in the Company or any of its subsidiaries.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to Mr. CHAU's re-designation is needed to be brought to the attention of the shareholders of the Company.

Mr. LAM Kit Sun

Mr. LAM Kit Sun, aged 45, is executive director, chief financial officer and company secretary of Universe Entertainment and Culture Group Company Limited (stock code: 1046), the securities of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited since August 2013. He has over 20 years' experience in the field of financial reporting, financial management and audit experience in the PRC and Hong Kong. He graduated from The Hong Kong University of Science and Technology with a bachelor's degree in Business Administration in Accounting. Mr. LAM is a fellow and practicing member of the Hong Kong Institute of Certified Public Accountants, a fellow member of the Association of Chartered Certified Accountants, an associate of The Hong Kong Chartered Governance Institute and a non-practicing member of the Chinese Institute of Certified Public Accountants.

Mr. LAM has not entered into any service contract for his duties as the independent non-executive Director with the Company. He will be entitled to receive an annual director's fee of HK\$60,000 which were determined by the Board based on recommendation of the remuneration committee of the Company and with reference to his relevant roles, duties and responsibilities in the Company, the prevailing market conditions and the Company's performance. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

As at the date of this announcement, save as disclosed above, Mr. LAM (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the SFO; (ii) does not hold any directorship in any Hong Kong or overseas listed public

companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the GEM Listing Rules) of the Company nor does he hold any position in the Company or any of its subsidiaries.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to Mr. LAM's appointment is needed to be brought to the attention of the shareholders of the Company.

Mr. LAM has confirmed that he meets the independence criteria as set out in Rule 5.09 of the GEM Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. CHAU and Mr. LAM for their new roles in the Company.

(3) CHANGE OF AUTHORISED REPRESENTATIVE AND COMPLIANCE OFFICER

The Board also announces that following the resignation of Mr. CHAN as the executive Director, with effect from 1 August 2022:

Mr. CHAN has ceased to act as the authorised representative (the “**Authorised Representative**”) and the compliance officer (the “**Compliance Officer**”) of the Company. In replacement of Mr. CHAN, Mr. CHAU, a new executive Director of the Company has been appointed as the Authorised Representative and Compliance Officer for the purpose of Rules 5.24 and 5.19 respectively of the Rules Governing the Listing of Securities on GEM (“**GEM**”) of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

(4) CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that with effect from 1 August 2022:

Mr. CHAN has resigned as the chairperson and member of the nomination committee of the Company (the “**Nomination Committee**”) and member of remuneration committee of the Company (the “**Remuneration Committee**”);

Following the re-designation of Mr. CHAU from independent non-executive Director to executive Director of the Company, he has ceased to act as a member of the audit committee of the Company (the “**Audit Committee**”); and

Mr. LAM, a new independent non-executive Director of the Company, has been appointed as a member of the Audit Committee and the Remuneration Committee and the chairperson and member of the Nomination Committee.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 1 August 2022

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. LAM Kit Sun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.